Статья
ФИКСИРОВАННАЯ КОМБИНАЦИЯ РАМИПРИЛА И ГИДРОХЛОРОТИАЗИДА: КОМУ И ДЛЯ ЧЕГО?
В настоящей статье рассматриваются аргументы "за" и "против" использования тиазидсодержащих комбинаций для лечения артериальной гипер-тензии в условиях реальной клинической практики. На основании данных доказательной медицины четко обозначены показания для эффективного и безопасного применения фиксированной комбинации рамиприла и гидрохлоротиазида.
1. Leonova MV, Shtejnberg LL, Belousov YB, et al. Pharmacoepidemiology of hypertension in in Russia: analysis of commitment of doctors (according to the study PIFAGOR IV). sistemnye gipertenzii 2015; 1: 19-25. Russian (Леонова М. В., Штейнберг Л. Л., Белоусов Ю. Б. и др. фармакоэпидемиология артериальной гипертонии в России: анализ приверженности врачей (по результатам исследования ПИфАГОР IV). системные гипертензии 2015; 1: 19-25).
2. Nedogoda s. V. Diuretics in arterial hypertension: angels and demons. Russ J Cardiol. 2013; 3 (101): 62-66. Russian (Недогода с. В. Диуретики при артериальной гипертен-зии: ангелы и демоны. Российский кардиологический журнал 2013; 3 (101): 62-66).
3. Messerli FH, Makani H, Bangalore s, et al. Hydrochlorothiazide is inappropriate for first-line antihypertensive therapy. European Meeting on Hypertension; June 12-16, 2009; Milan, Italy. Abstract LB1.3.
4. Chen JMH, Heran Bs, Wright JM, et al. Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. Cochrane Database syst Rev 2009; 4: CD007187.
5. Agabiti-Rosei E, Ambrosioni E, Dal Pal C, et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group J. Hypertens 1995; 13 (11): 1325-34.
6. Williams B, Lacy Ps, Thom sM, et al. Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes Principal Results of the Conduit Artery Function Evaluation (CAFE) study Circulation 2006; 113: 1213-25.
7. Matsui Y, O'Rourke MF, Hoshide s, et al. Combined Effect of Angiotensin II Receptor Blocker and Either a Calcium Channel Blocker or Diuretic on Day-by-Day Variability of Home Blood Pressure The Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy study Hypertension 2012; 59: 1132-8.
8. Zillich AJ, Garg J, Basu s, et al. Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review. Hypertension 2006; 48(2): 219-24.
9. Bhushan B, Gupta s, Khajuria V, et al. Comparative Efficacy and safety of Triple Therapy (Ramipril, Telmisartan, Hydrochlorothiazide) Vs Dual AntiHypertensive Therapy (Ramipril or Telmisartan, Hydrochlorothiazide) in stage 2 Hypertensive Patients Journal of Clinical and Diagnostic Research 2014; 8(8): 25-8.
10. Xagar B, Vozelj s, Golob J. Ramipril and ramipril fixed-dose combinations with hydrochlorothiazide in the treatment of hypertensive patients KardioList 2010; 5(7): 100.
11. scholze J. short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. Journal of Hypertension; 1993; 11: 217-21.
12. Heidbreder D, et al. Combination of Ramipril and Hydrochlorothiazide in the Treatment of Mild to Moderate Hypertension: Part 1-A Double-Blind, Comparative, Multicenter study in Nonresponders to Ramipril Monotherapy. Clin. Cardiol. 1992; 15: 904-10.
13. Modesti PA, Rocchi F, Tedeschini RC, et al. Blood Pressure Response to Combination Therapy with Ramipril or Captopril Plus Hydrochlorothiazide: A Randomized, Active-Controlled, Crossover study Curr Ther Res 2001; 62: 16-25.
14. Lonn E, Yusuf s, Dzavik V, et al. sECURE Investigators Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (sECURE) Circulation 2001; 103 (7): 919-25.
15. Pitt B, O'Neill B, Feldman R, et al. QUIET study Group. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function Amer. J. Cardiology 2001; 87 (9): 1058-63.
16. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The simvastatin/ Enalapril Coronary Atherosclerosis Trial (sCAT) Circulation 2000; 102 (15): 1748-54.
17. Kaplan NM. The CARE study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators Clin Ther. 1996; 18 (4): 658-70.
18. Livre M, Guret P, Gayet C. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR study Group Hypertension 1995; 25 (1): 92-7.
19. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) study Investigators Lancet 1993; 342 (8875): 821-8.
20. Hall As, Murray GD, Ball sG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) study. Acute Infarction Ramipril Efficacy Lancet 1997; 349: 1493-7.
21. Wienbergen H, schiele R, Gitt AK, et al. MITRA PLUs study Group Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with sT-elevation acute myocardial infarction Amer. J. Cardiology 2002; 90 (10): 1045-9.
22. Heart Outcomes Prevention Evaluation study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 2000; 22 (355): 253-9.
23. Yusuf s, sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation study Investigators New Engl. J. Med. 2000; 342 (3): 145-53.
24. Braunwald E, Domanski MJ, Fowler sE, et al. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease New Engl. J Med. 2004; 351 (20): 2058-68.
25. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement Amer. Heart J. 1991; 121 (Pt 1): 1244-63.
26. Marre M, Lievre M, Chatellier G, et al. DIABHYCAR study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomized, double blind, placebo controlled trial (the DIABHYCAR study) BMJ 2004; 328 (7438): 495.
27. Wright JTJr, Bakris G, Greene T, et al. African American study of Kidney Disease and Hypertension study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AAsK trial JAMA 2002; 288 (19): 2421-31.
28. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria Lancet 1999; 354: 359-64.
29. Carl J. Pepine HOPE-TOO: Extended use of ACEI reduces CV risk and new diabetes, independent of baseline risk Data Alert www.VBWG.org
30. Wright JT, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus standard Blood-Pressure Control N Engl J Med 2015; 373: 2103-16.